Suzhou, China

Qunmin Zhou


 

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Jiangsu, CN (2017)
  • Suzhou, CN (2022 - 2024)

Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Qunmin Zhou in Monoclonal Antibody Development

Introduction

Qunmin Zhou is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of biotechnology. He holds a total of five patents, focusing primarily on monoclonal antibodies that target specific antigens for therapeutic applications. His work has the potential to advance treatments for various tumors and diseases.

Latest Patents

One of Qunmin Zhou's latest patents is a monoclonal antibody specifically binding to human and monkey CD38 antigens. This invention includes detailed amino acid sequences for the complementarity-determining regions of both the light and heavy chain variable regions of the antibody. The monoclonal antibody can be utilized in pharmaceutical compositions for treating tumors with positive CD38 expression, such as human myeloma and lymphoma.

Another notable patent involves a monoclonal antibody that binds to the human TIGIT antigen. This antibody has high affinity and antagonistically inhibits the binding of TIGIT to its ligand, CD155. The patent outlines the amino acid sequences for the complementarity-determining regions of the antibody, along with a humanization preparation method. This antibody can also be used in pharmaceutical compositions for treating various tumors.

Career Highlights

Qunmin Zhou has worked with several companies in the biotechnology sector, including Acroimmune Biotech Co., Ltd. and Acroimmune Biopharma Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Throughout his career, Qunmin Zhou has collaborated with notable professionals in the field, including Hongqun Hu and Zui Chen. These collaborations have likely enhanced his research and development efforts in monoclonal antibody technology.

Conclusion

Qunmin Zhou's innovative work in monoclonal antibody development showcases his commitment to advancing medical treatments. His patents reflect a deep understanding of biotechnology and its applications in treating serious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…